The research proposed here seeks to define the efficacy of the use of orange peel oil as an anticarcinogen while further defining its mechanism of action in this role. To accomplish this HPLC techniques will be used to isolate the components of orange peel oil. The anticarcinogenic potency of these components will be quantitated by feeding them in a totally defined diet to rats exposed to DMBA. Carcinogen specificity will be defined by testing the ability of the orange peel oil anticarcinogen(s) to inhibit both spontaneous and induced mammary tumors. Organ specificity will be examined by testing the ability of the orange peel oil anticarcinogen(s) to inhibit neoplastic changes in mammary gland, skin and bladder. Species specificity studies will compare the response of carcinogen exposed rats and mice to orange oil anticarcinogens. In addition, similar in vitro comparisons will be made using rat and human primary parenchymal cells from mammary gland and liver. Individual specificity will be modeled with rat strains possessing high or low sensitivity to the induction of mammary carcinomas. All animal experiments will be analyzed using both parametric and nonparametric statistical procedures. Once the anticarcinogen is identified its pharmacokinetics and metabolism will be defined. The biological activity of these metabolites will be determined. The mechanism(s) of action of the orange peel oil anticarcinogen(s) and/or its metabolites will be studied.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA038128-07
Application #
3176166
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1984-07-01
Project End
1995-02-28
Budget Start
1992-03-01
Budget End
1993-02-28
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Berchtold, Craig M; Chen, Kai-Shun; Miyamoto, Shigeki et al. (2005) Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res 65:8558-66
Clark, S S; Perman, S M; Sahin, M B et al. (2002) Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16:213-22
Ariazi, E A; Gould, M N (1996) Consecutive cycles of precise, unidirectional 14-bp deletions using a BseRI/BsgI trimming plasmid. Biotechniques 20:446-8, 450-1
Gelb, M H; Tamanoi, F; Yokoyama, K et al. (1995) The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 91:169-75
Mills, J J; Chari, R S; Boyer, I J et al. (1995) Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55:979-83
Shi, W; Gould, M N (1995) Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. Cancer Lett 95:1-6
Gould, M N; Moore, C J; Zhang, R et al. (1994) Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras. Cancer Res 54:3540-3
Crowell, P L; Elson, C E; Bailey, H H et al. (1994) Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol 35:31-7
Haag, J D; Gould, M N (1994) Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34:477-83
Crowell, P L; Ren, Z; Lin, S et al. (1994) Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47:1405-15

Showing the most recent 10 out of 26 publications